241 related articles for article (PubMed ID: 33264017)
1. Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Wang H; Ren B; Liu Y; Jiang B; Guo Y; Wei M; Luo L; Kuang X; Qiu M; Lv L; Xu H; Qi R; Yan H; Xu D; Wang Z; Huo CX; Zhu Y; Zhao Y; Wu Y; Qin Z; Su D; Tang T; Wang F; Sun X; Feng Y; Peng H; Wang X; Gao Y; Liu Y; Gong W; Yu F; Liu X; Wang L; Zhou C
J Med Chem; 2020 Dec; 63(24):15541-15563. PubMed ID: 33264017
[TBL] [Abstract][Full Text] [Related]
2. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Xiong Y; Guo Y; Liu Y; Wang H; Gong W; Liu Y; Wang X; Gao Y; Yu F; Su D; Wang F; Zhu Y; Zhao Y; Wu Y; Qin Z; Sun X; Ren B; Jiang B; Jin W; Shen Z; Tang Z; Song X; Wang L; Liu X; Zhou C; Jiang B
Neoplasia; 2020 Sep; 22(9):431-440. PubMed ID: 32652442
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
4. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
5. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement.
Wigle TJ; Blackwell DJ; Schenkel LB; Ren Y; Church WD; Desai HJ; Swinger KK; Santospago AG; Majer CR; Lu AZ; Niepel M; Perl NR; Vasbinder MM; Keilhack H; Kuntz KW
Cell Chem Biol; 2020 Jul; 27(7):877-887.e14. PubMed ID: 32679093
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.
Velagapudi UK; Langelier MF; Delgado-Martin C; Diolaiti ME; Bakker S; Ashworth A; Patel BA; Shao X; Pascal JM; Talele TT
J Med Chem; 2019 Jun; 62(11):5330-5357. PubMed ID: 31042381
[TBL] [Abstract][Full Text] [Related]
9. Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
Jain MR; Mohapatra J; Bandhyopadhyay D; Chatterjee A; Ghoshdastidar K; Patel D; Patel A; Bhayani H; Srivastava BK; Shedage SA; Kadam P; Sundar R; Patel H; Giri P; Patel P; Gupta L; Srinivas NR; Patel PR; Desai RC
Cancer Chemother Pharmacol; 2018 Oct; 82(4):635-647. PubMed ID: 30046848
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Quinazoline-2,4(1
Zhou J; Ji M; Wang X; Zhao H; Cao R; Jin J; Li Y; Chen X; Sheng L; Chen X; Xu B
J Med Chem; 2021 Nov; 64(22):16711-16730. PubMed ID: 34748333
[TBL] [Abstract][Full Text] [Related]
12. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A
Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.
Chen X; Huan X; Liu Q; Wang Y; He Q; Tan C; Chen Y; Ding J; Xu Y; Miao Z; Yang C
Eur J Med Chem; 2018 Feb; 145():389-403. PubMed ID: 29335205
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
[TBL] [Abstract][Full Text] [Related]
18. Human Mass Balance and Metabolite Profiling of [
Mu S; Palmer D; Fitzgerald R; Andreu-Vieyra C; Zhang H; Tang Z; Su D; Sahasranaman S
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1108-1120. PubMed ID: 33876576
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
